Participants 76 141 3
in nondiabetic patients with stage I or II chronic kidney disease
Participants 736 848 4
Thirty nondiabetic stage I or II CKD patients who had already been treated with angiotensin II receptor blockers
Participants 996 1141 4
METHODS Patients were randomly divided into 2 groups; one group was treated with 16 mg azelnidipine and the other with 5 mg amlodipine once daily
